Navigation Links
Targeted antibacterial agent rapidly created in response to serious food safety pathogen

South San Francisco, CA (March 14, 2012): A highly targeted bactericidal protein against the life-threatening foodborne E. coli O104 strain was rapidly created using AvidBiotics' antibacterial Purocin protein technology, making use of rapidly acquired, published, draft genomic sequence data as detailed in a new publication in PLoS ONE. The strategy described offers a rapid-response platform with the potential to create targeted agents for use against emerging bacterial pathogens within days-to-weeks of acquiring the pathogen's genome sequence.

"AvidBiotics has created a highly versatile technology platform for the generation of antibacterial proteins that specifically target and rapidly kill bacterial strains, offering important benefits in food security," said AvidBiotics' scientist, Dean Scholl, Ph.D., lead author on the new publication. "In collaboration with scientists from the U.S. Department of Agriculture, we've now shown that we can quickly generate such Purocin proteins against an emerging pathogen using only data acquired from its genome sequence, without necessarily having immediate access to the pathogen itself. This technology, in combination with the ever-increasing speed in which genome sequences can be generated and DNA synthesized, should provide a valuable tool for responding to newly emerging, re-emerging, and ever-changing bacterial threats." The E. coli O104 strain, which initially emerged in Germany in spring 2011, was ultimately responsible for close to 4,000 illnesses and 48 deaths.

The AvidBiotics authors and their collaborators at the U.S. Department of Agriculture, Western Regional Research Center, describe how, using published genomic data from the German E. coli outbreak strain, they identified an O-antigen-specific prophage tail spike protein encoded in the pathogen's genome. They synthesized the identified gene and fused it to the tail fiber gene of an R-type bacteriocin (a defense protein produced by certain bacteria against competing strains), and expressed the novel, engineered, antibacterial protein so that the tail fiber fusion was incorporated into an R-type bacteriocin structure. The resulting engineered protein demonstrated the ability to specifically bind and rapidly kill all tested E. coli strains that produce the O104 lipopolysaccharide antigen, including the German outbreak strain isolated from affected patients. None of many tested E. coli strains lacking the O104 antigen was sensitive to the O104-targeted protein, ensuring no unintended collateral damage.

About the AvidBiotics Antibacterial Protein Platform

AvidBiotics genetically engineers bactericidal proteins from R-type bacteriocins, proteins produced by some Pseudomonas aeruginosa strains for the purpose of killing competing bacteria. AvidBiotics' antibacterial proteins specifically kill bacteria by binding to the bacterial cell and punching a hole in the cell envelope, causing membrane depolarization and rapid cell death.

AvidBiotics has previously demonstrated that Purocin proteins can be engineered to recognize and kill in a highly targeted and specific manner a variety of bacteria, including E. coli, Salmonella, and Shigella, thus serving as a platform for the production of numerous highly specific antibacterial agents. AvidBiotics is collaborating with food safety and hygiene company, Ecolab, Inc. (NYSE: ECL), to develop antibacterial proteins for use against E. coli O157:H7 in processing meat and other foods.

In addition to E. coli, a cause of both serious diarrheal disease and recurrent urinary tract infections, AvidBiotics is also currently developing Avidocin proteins against Pseudomonas aeruginosa, a common cause of severe pneumonia and wound infections, Clostridium difficile, the most common cause of hospital-acquired infections, and Acinetobacter, a bacterium associated with serious, often broadly antibiotic-resistant infections in Intensive Care Units and with injuries incurred by U.S. military deployed in Iraq and Afghanistan.


Contact: Joan Kureczka
Kureczka/Martin Associates

Related biology technology :

1. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
2. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
3. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
4. Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
5. Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer
6. Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
7. Epeius Biotechnologies REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
8. Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
9. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
10. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
11. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
Post Your Comments:
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Twist ... announced that Emily Leproust, Ph.D., Twist Bioscience chief ... Jaffray Healthcare Conference on December 1, 2015 at ... Hotel in New York City. --> ... . Twist Bioscience is on Twitter. ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., ... authentication to mobile and PC devices, announced its ActiveIRIS® ... the arrows NX F-02H launched by NTT DOCOMO, INC ... F-02H is the second smartphone to include iris recognition ... in ARROWS NX F-04G in May 2015, world,s first ...
Breaking Biology News(10 mins):